An institutional review of tumour biology of breast cancer in young Nepalese women

  • Bikash Nepal
  • Yogendra Singh
  • Prakash Sayami
  • Gita Sayami

Abstract

Introduction: Breast cancers in <40 years of age group usually presents with aggressive biology and has poor prognosis. The aim of this study was to see clinic-pathological and hormone receptors of breast cancers in young women and compare with less than 40 year age group.Methods : Prospective analysis of 97 breast cancer in patients less than 40 years out of total 373 patients (26%) over a period of 8 years (2007 Jan to 2014 Dec) was carried out at the Department of Surgery, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.Result: Among the young women diagnosed with breast cancer, the mean age was 34.5±6.2 years. Mean tumour size was larger in younger women (5±2.5 vs 4.5±2.4 cm). Locally advanced disease was higher in younger patients (55% vs 47%). Lymphatic and vascular invasions were higher (63% vs 35% and 40% vs 25%). Grade II and  III tumours was higher (56% vs 25%). ER, PR and HER2 positivity was detected in 46.9%, 48.9% and 28.9%, respectively. Significant lower ER/or PR expression (34.5% vs 54%) was seen in younger women, p=.002.Triple negative tumours (ER-, PR- and HER2-ve) was proportionately higher in younger patients (23% vs 13.7%, p=.043).Conclusions: Young Nepalese women presents one quarter of all female breast cancers, more frequently locally advanced with aggressive tumour biology like ER/PR negative and triple negative breast cancers.

References

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108

2. Freedman RA, Partridge AH. Management of breast cancer in very young women. Breast,2013;2:176-9

3. Stewart BW, Wild C; International Agency for Research on Cancer; World Health Organization. World Cancer Report 2014. Geneva: World Health Organization; 2014

4. Brinton LA, Sherman ME, Carreon JD, Anderson WF. Recent Trends in Breast Cancer Among Younger Women in the United States. JNCI Journal of the National Cancer Institute. 2008;100:1643-1648.

5. Figueroa JD, Brinton LA. Unraveling Genes, Hormones, and Breast Cancer.JNCI Journal of the National Cancer Institute. 2012;104:641-642.

6. Barber MD, Jack W, Dixon JM. Diagnostic delay in breast cancer. Br J Surg 2004;91:49-53

7. Sidoni A, Cavaliere A, Bellezza G, Scheibel M, Bucciarelli E. Breast cancer in young women: Clinicopathological features and biological specificity. Breast 2003;12:247-50

8. Barber MD, Jack W, Dixon JM. Diagnostic delay in breast cancer. Br J Surg 2004;91:49-53.

9. Friedman LC, Kalidas M, Elledge R, Dulay MF, Romero C, Chang J, et al. Medical and psychosocial predictors of delay in seeking medical consultation for breast symptoms in women in a public sector setting. J Behav Med 2006;29:327-34

10. Gurleyik G, Gurleyik E, Aktekin A, Aker F. Preoperative Assessment of the Axilla by Surgeon Performed Ultrasound and Cytology in Patients With Breast Cancer. Journal of Clinical Medicine Research. 2015;7:440-445.

11. John S Meyer, Consuelo Alvarez, Clara Milikowski, Neal Olson, Irma Russo,Jose Russo, Andrew Glass, Barbara A Zehnbauer:Breast carcinoma malignancy grading by Bloom–Richardson system vs proliferation index: reproducibility of grade and advantagesof proliferation index. Modern Pathology 2005,18:1067–1078.

12. Speirs V, Kerin MJ: Prognostic significance of oestrogen receptor beta in breast cancer. Br J Surg 2000, 87:405-409.

13. Donegan WL: Tumor-related prognostic factors for breast cancer. CA Cancer J Clin 1997, 47:28-51

14. Skoog L, Humla S, Axelsson M, Frost M, Norman A, Nordenskjold B, Wallgren A: Estrogen receptor levels and survival of breast cancer patients. A study on patients participating in randomized trials of adjuvant therapy. ActaOncol 1987, 26:95-100

15. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.

16. Anders C, Carey LA: Understanding and treating triple-negative breast cancer. Oncology.2008, 22:1233-1239.

17. Irvin WJ Jr, Carey LA: What is triple-negative breast cancer? Eur J Cancer.2008 44:2799-2805.

18. Rakha EA, Reis-Filho JS, Ellis IO: Basal-like breast cancer: A critical review. J Clin Oncol.2008, 26: 2568-2581.

19. Han-Byoel Lee1, Wonshik Han. Unique Features of Young Age Breast Cancer and Its Management. J Breast Cancer 2014; 17: 301-307
Published
2017-08-10
How to Cite
NEPAL, Bikash et al. An institutional review of tumour biology of breast cancer in young Nepalese women. J Soc Surg Nep, [S.l.], v. 18, n. 2, p. 16-19, aug. 2017. ISSN 2392-4772. Available at: <http://jssn.org.np/index.php?journal=jssn&page=article&op=view&path%5B%5D=234>. Date accessed: 24 feb. 2021.
Section
Original Article